Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.790 +0.140 (+8.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators. 
Via Benzinga
Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – 
From Coherus Oncology, Inc.
Via GlobeNewswire
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
 
Via Benzinga
Coherus Oncology to Participate in Upcoming Investor Conferences
From Coherus Oncology, Inc.
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Insights Ahead: Coherus BioSciences's Quarterly Earnings
 
Via Benzinga
Coherus (CHRS) Q2 Revenue Jumps 10%
Via The Motley Fool
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
From Coherus Oncology, Inc.
Via GlobeNewswire
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
From Coherus Oncology, Inc.
Via GlobeNewswire
Which stocks are moving after the closing bell on Friday?
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
Earnings Scheduled For May 12, 2025
 
Via Benzinga
Earnings Preview: Coherus BioSciences
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor – 
From Coherus BioSciences, Inc.
Via GlobeNewswire
Top movers in Friday's after hours session
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Which stocks are moving before the opening bell on Tuesday?
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Participate in Upcoming Investor Conferences
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Which stocks are moving after the closing bell on Wednesday?
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
Earnings Scheduled For March 10, 2025
 
Via Benzinga
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.